Aug 1, 2024 SOURCE: PR NewsWire

Nucleic Acid Therapeutics Market to Reach USD 22.1 Billion by 2034, Advances in Genetic Research and Biotechnology Propel Growth: Transparency Market Research Inc.

This has increased the therapeutic efficacy and safety profiles of these medicines, resulting in significant nucleic acid therapeutics market development.

WILMINGTON, Del., Aug. 1, 2024 /PRNewswire/ -- According to Transparency Market Research, the scope for nucleic acid therapeutics is immense in the forthcoming decade. With an astounding CAGR of 12.8%, the market is forecast to attain a valuation of US$ 22.1 billion by 2034. As of 2023, the nucleic acid therapeutics landscape was valued at US$ 6 billion.

https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

Advances in genetic research and biotechnology are propelling the nucleic acid therapeutics market value. These medicines, which include antisense oligonucleotides (ASOs), RNA interference (RNAi), and RNA aptamers, provide targeted treatments for a range of genetic abnormalities, infectious diseases, and malignancies.

Download Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86333

ASOs have the largest market share due to their strong therapeutic properties; they are effective in treating rare genetic disorders such as Duchenne muscular dystrophy and spinal muscular atrophy. RNAi medicines, with their great specificity in gene silencing, are expected to witness substantial market progress, fueled by successful drugs such as patisiran and givosiran. RNA aptamers, albeit being rare, show great potential because of their unique targeting capabilities.

The creation of synthetic oligonucleotides has resulted in substantial advances in nucleic acid treatments. To improve their medicinal capabilities, synthetic oligonucleotides undergo certain chemical changes. These alterations can take place at three different sites: the nucleobase, the ribofuranose unit, and the phosphate backbone.

Altering the nucleobase and ribose units can shield oligonucleotides against enzymatic damage, thus enhancing their stability within the body, whereas modification of the phosphate backbone can make nucleotide chains less negatively charged, thus promoting their cellular uptake and target localization.

Nucleic Acid Therapeutics Market Report Scope:



     
              Report Coverage 
     
              Details



     Forecast Period            
     2024-2034



     Base Year                  
     2020-2022



     Size in 2023               
     US$ 6.0 Bn



     Forecast (Value) in 2034   
     US$ 22.1 Bn



     Growth Rate (CAGR)                                            12.8 %



     No. of Pages               
     195 Pages



     Segments covered             By Product, By Indication, By End-user,
                                    By Region

Competitive Landscape

The market for nucleic acid therapeutics is highly competitive and has a strong presence of key players. The nucleic acid therapeutics market report highlights that leading players are adopting strategies such as acquisition and launch of new products. Key players operating in the nucleic acid therapeutics domain include:

    --  Alynylam Pharmaceutials Inc.
    --  BioNTech
    --  Ionis Pharmaceuticals Inc.
    --  Moderna
    --  Nippon Shinyaku
    --  Novartis
    --  Pfizer
    --  Sarepta Therapeutics
    --  Biogen Inc.
    --  Genzyme Sanofi
    --  Percheron Therapeutics Ltd.
    --  Other Prominent Players

Key Market Developments

    --  In April 2024, autogene cevumeran, an RNA-based cancer treatment that
        stimulates the immune system to target and kill pancreatic cancer cells,
        was investigated in a clinical trial by the Memorial Sloan Kettering
        Cancer Center. This stops existing cancer as well as avoids more illness
        with the help of a strong immune system.
    --  In December 2023, Ionis Pharmaceuticals expanded its Carlsbad's facility
        for improving its nucleotide-based therapeutics capabilities, expecting
        support for product investment as well as clinical trials so as bring in
        more innovative nucleotide drugs into the market, which constitutes the
        main theme of its antisense technology.

Key Takeaways from the Market Report

    --  In 2024, the nucleic acid therapeutics market is expected to total US$
        6.8 billion.
    --  From 2024 to 2034, the market is anticipated to expand 3.2x.
    --  By product, demand for anti-sense oligonucleotides (ASO) is expected to
        be high, attributed to their capacity to specifically target and modify
        gene expression.
    --  By indication, genetic disorders are expected to be primary areas for
        nucleic acid therapeutics.

Key Market Drivers and Trends

    --  Modifications of chemical structure of genes address the fundamental
        constraints of native oligonucleotides, which include low stability and
        poor physicochemical characteristics.
    --  As a result, these changes vividly improve the pharmacokinetic
        characteristics of oligonucleotide-based treatments, making them more
        promising for clinical usage.
    --  Because of their increased stability and efficiency, nucelic acid based
        drugs can now be used to treat a wide spectrum of ailments, including
        genetic abnormalities and malignancies.
    --  Hence, improved efficacy and safety profiles of the new synthetic
        oligonucleotides and innovative gene editing technologies are fueling
        the nucleic acid therapies market size.

Explore Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86333

Regional Profile

    --  North America promises to yield significant expansion opportunities for
        nucleic acid therapeutics. Excellent research and development
        infrastructure, robust regulatory environment, and high prevalence of
        genetic abnormalities and diseases treated with these therapies are
        driving market dynamics.
    --  The United States, in particular, is home to prominent biotechnology and
        pharmaceutical businesses that invest in cutting-edge technologies such
        as CRISPR-Cas gene editing and synthetic oligonucleotides. The region's
        well-established regulatory system, which includes clear standards from
        agencies such as the FDA, promotes innovation and supports the timely
        launch of innovative treatments.
    --  Good legislation and more clinical trials are driving the nucleic acid
        therapeutics market revenue in Europe. Furthermore, with improved
        technology and access to better healthcare, Asia Pacific is becoming a
        lucrative market.

Key Segments Profiled

Product

    --  Anti-sense Oligonucleotides (ASO)
    --  RNA Interference (RNAi)
    --  RNA Aptamers

Indication

    --  Autoimmune Disorders
    --  Infectious Diseases
    --  Genetic Disorders
    --  Cancer
    --  Others (Neurodegenerative Diseases, etc.)

End User

    --  Hospitals
    --  Physicians' Offices
    --  Others (Academics and Research Institutes, etc.)

Region

    --  North America
    --  Latin America
    --  Europe
    --  Asia Pacific
    --  Middle East & Africa

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=86333&ltype=S

More Trending Report by Transparency Market Research:

    --  Operating Room Integration Market - With a projected CAGR of 13.9% for
        the next ten years, the market is likely to reach a valuation of nearly
        US$ 7.2 Bn by the end of 2032.
    --  Near Infrared Imaging Market - Preclinical Imaging is expected to be the
        highest revenue-generating application, projected to grow at a CAGR of
        over 14.2% during 2022 - 2032.
    --  Single-use Flexible Endoscope Market is projected to advance at a CAGR
        of 23.9% between 2022 and 2031 and reach more than US$ 9.1 Bn by the end
        of 2031

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn | Twitter | Blog | YouTube